Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Partially-blind Multi-centric Study in Adults Aged Between 18-60 Years Designed to Evaluate the Reactogenicity and Immunogenicity of 1 and 2 Doses of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) Administered at Different Doses and Adjuvanted or Not

NCT00309647 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00309647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00309647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Partially-blind Multi-centric Study in Adults Aged Between 18-60 Years Designed to Evaluate the Reactogenicity and Immunogenicity of 1 and 2 Doses of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) Administered at Different Doses and Adjuvanted or Not
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
March 29, 2006
Completion date
November 16, 2006
Enrollment
400 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

influenza